Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 known ✓ | P08172 | 1/20 | 0.83 |
| ▸ | CHRM4 known ✓ | P08173 | 1/20 | 0.83 |
| ▸ | HTR1A known ✓ | P08908 | 1/20 | 0.83 |
| ▸ | CHRM5 known ✓ | P08912 | 1/20 | 0.83 |
| ▸ | ADRA2A known ✓ | P08913 | 1/20 | 0.83 |
| ▸ | CHRM1 known ✓ | P11229 | 1/20 | 0.83 |
| ▸ | ADRA2B known ✓ | P18089 | 1/20 | 0.83 |
| ▸ | ADRA2C known ✓ | P18825 | 1/20 | 0.83 |
| ▸ | CHRM3 known ✓ | P20309 | 1/20 | 0.83 |
| ▸ | DRD1 known ✓ | P21728 | 1/20 | 0.83 |
| ▸ | ACHE known ✓ | P22303 | 1/20 | 0.83 |
| ▸ | SLC6A2 known ✓ | P23975 | 1/20 | 0.83 |
| ▸ | HRH2 known ✓ | P25021 | 1/20 | 0.83 |
| ▸ | ADRA1D known ✓ | P25100 | 1/20 | 0.83 |
| ▸ | HTR2A known ✓ | P28223 | 1/20 | 0.83 |
| ▸ | OPRM1 known ✓ | P35372 | 1/20 | 0.83 |
| ▸ | DRD3 known ✓ | P35462 | 1/20 | 0.83 |
| ▸ | SCN1A known ✓ | P35498 | 1/20 | 0.83 |
| ▸ | SLC6A3 known ✓ | Q01959 | 1/20 | 0.83 |
| ▸ | KCNH2 known ✓ | Q12809 | 1/20 | 0.83 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL7521593 | 1.00 | KMT2A (0.84) | KMT2AUSP2MEN1KDM4ELMNA | |
| SCHEMBL4995816 | 0.99 | USP2 (0.84) | KMT2AUSP2MEN1KDM4ELMNA | |
| SCHEMBL4995822 | 0.99 | USP2 (0.84) | KMT2AUSP2MEN1KDM4ELMNA | |
| SCHEMBL29359029 | 0.99 | USP2 (0.84) | KMT2AUSP2MEN1KDM4ELMNA | |
| SCHEMBL30583375 | 0.95 | USP2 (0.90) | KMT2AUSP2MEN1KDM4ELMNA | |
| Quinacrine SCHEMBL162379 | 0.92 | USP2 (1.00) | KMT2AUSP2MEN1KDM4ELMNA | |
| Quinacrine SCHEMBL33693 | 0.92 | USP2 (1.00) | KMT2AUSP2MEN1KDM4ELMNA | |
| Quinacrine SCHEMBL15061349 | 0.92 | USP2 (1.00) | KMT2AUSP2MEN1KDM4ELMNA | |
| Quinacrine SCHEMBL30153780 | 0.92 | USP2 (1.00) | KMT2AUSP2MEN1KDM4ELMNA | |
| Quinacrine SCHEMBL498442 | 0.92 | USP2 (1.00) | KMT2AUSP2MEN1KDM4ELMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12616662-B2 | Lipid particles for nucleic acid delivery and clinical applications of same | RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) | 2026-05-05 | — | — | US | disclosed |
| US-12523664-B2 | Sensor chip and methods thereof | NATIONAL UNIVERSITY OF SINGAPORE (SG) | 2026-01-13 | — | — | US | disclosed |
| US-20250312347-A1 | THERAPEUTIC BENEFIT OF SUBOPTIMALLY ADMINISTERED CHEMICAL COMPOUNDS | BROWN DENNIS M (US) | 2025-10-09 | — | — | US | disclosed |
| US-12398425-B2 | Antidote-mediated reversal of extracellular aptamer staining | DUKE UNIVERSITY (US) | 2025-08-26 | — | — | US | disclosed |
| US-12336993-B2 | Therapeutic benefit of suboptimally administered chemical compounds | BROWN DENNIS M (US) | 2025-06-24 | — | — | US | disclosed |
| US-20250057924-A1 | METHODS AND COMPOSITIONS FOR IMPROVED MOLECULAR THERAPIES OF MULTIGENIC DISEASES | SOBOL ROBERT E (US) | 2025-02-20 | — | — | US | disclosed |
| US-12181972-B1 | System-wide constraints on retries within distributed applications | AMAZON TECHNOLOGIES, INC. (US) | 2024-12-31 | — | — | US | disclosed |
| US-20240141430-A1 | ANTIDOTE-MEDIATED REVERSAL OF EXTRACELLULAR APTAMER STAINING | DUKE UNIVERSITY | 2024-05-02 | — | — | US | disclosed |
| US-20240052043-A1 | ANTIBODIES THAT BIND EGFR AND ERBB3 | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2024-02-15 | — | — | US | disclosed |
| CN-115137061-B | Treatment method for improving antioxidant activity and nutritional value of basil seeds | 余辉 | 2024-01-02 | — | — | CN | disclosed |
| US-20230156932-A1 | Optical Communication Element | NTT, INC. (JP) | 2023-05-18 | — | — | US | disclosed |
| US-20230133044-A1 | THERAPEUTIC BENEFIT OF SUBOPTIMALLY ADMINISTERED CHEMICAL COMPOUNDS | BROWN DENNIS M (US) | 2023-05-04 | — | — | US | disclosed |
| US-11634772-B2 | Antidote-mediated reversal of extracellular aptamer staining | DUKE UNIVERSITY (US) | 2023-04-25 | — | — | US | disclosed |
| EP-4153560-A1 | LIPID PARTICLES FOR NUCLEIC ACID DELIVERY AND CLINICAL APPLICATIONS OF SAME | Ramot at Tel-Aviv University Ltd. (IL) | 2023-03-29 | — | — | EP | disclosed |
| US-20220397580-A1 | METHOD OF DETECTING A NEURODEGENERATIVE DISEASE | NATIONAL UNIVERSITY OF SINGAPORE (SG) | 2022-12-15 | — | — | US | disclosed |
| US-20220373562-A1 | SENSOR CHIP AND METHODS THEREOF | NATIONAL UNIVERSITY OF SINGAPORE (SG) | 2022-11-24 | — | — | US | disclosed |
| US-11491154-B2 | Therapeutic benefit of suboptimally administered chemical compounds | BROWN DENNIS M (US) | 2022-11-08 | — | — | US | disclosed |
| EP-4065692-A2 | MESENCHYMAL STEM CELLS WITH ENHANCED THERAPEUTIC PROPERTIES | Cells For Cells S.A. (CL) | 2022-10-05 | — | — | EP | disclosed |
| US-20220290105-A1 | MESENCHYMAL STEM CELLS WITH ENHANCED THERAPEUTIC PROPERTIES | CELLS FOR CELLS S A (CL) | 2022-09-15 | — | — | US | disclosed |
| CN-108504765-B | Real-time fluorescent PCR (polymerase chain reaction) fungus detection primer, probe, kit and detection method | 杭州千基生物科技有限公司 | 2022-04-01 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230133044-A1 | THERAPEUTIC BENEFIT OF SUBOPTIMALLY ADMINISTERED CHEMICAL COMPOUNDS | UNG, DPYD, TPMT | CHRM2 4003/4885CHRM4 4658/4885HTR1A 4764/4885 |
| US-20250312347-A1 | THERAPEUTIC BENEFIT OF SUBOPTIMALLY ADMINISTERED CHEMICAL COMPOUNDS | UNG, DPYD, TPMT | CHRM2 4003/4885CHRM4 4658/4885HTR1A 4764/4885 |
| US-11491154-B2 | Therapeutic benefit of suboptimally administered chemical compounds | UNG, DPYD, TPMT | CHRM2 4003/4885CHRM4 4658/4885HTR1A 4764/4885 |
| US-12336993-B2 | Therapeutic benefit of suboptimally administered chemical compounds | UNG, DPYD, TPMT | CHRM2 4003/4885CHRM4 4658/4885HTR1A 4764/4885 |
| US-12616662-B2 | Lipid particles for nucleic acid delivery and clinical applications of same | APOB, APOL1, SLC27A1 | CHRM2 3581/4885CHRM4 4427/4885HTR1A 2674/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.